Response to comment regarding “Immunosuppression Following Fresh Arterial Homograft Implantation for Aortic Graft Infections”  by Pupka, A. et al.
Eur J Vasc Endovasc Surg (2011) 41, 859e860CORRESPONDENCEImmunosuppression following Fresh Arterial
Homograft Implantation for Aortic Graft InfectionsDOI of original article: 10.1016/j.ejvs.2011.03.005.We read with great interest the report of Pupka et al.
comparing fresh arterial homografts (FAH) and silver-
coated grafts to treat aortic graft infections, since we
obtained similar results with cryopreserved homografts.1,2
Beyond that, the paper contains important data about
another matter of active debate, namely immunosuppres-
sion after FAH. The authors can be congratulated on their
study protocol that allows for the first clinical comparison
of FAH with and without immunosuppressive therapy.
Unfortunately, this item was not taken up in the discussion.
The authors advocate immunosuppression early following
implantation and believe to prevent consecutive degener-
ation due to less late complications in this group.1 However,
the study lacks information about HLA/ABO matching. We
would encourage the authors to look up these data as well.
While in CAH and infection no correlation between ABO-
incompatibility and outcome was found, this question has
not been answered for FAH yet.2
Lymphocyte scintigraphy was used for patient surveil-
lance. We think that the results should be interpreted with
caution. The method does not allow distinguishing between
rejection and infection. Both conditions are reflected by the
same scintigraphic findings. Therefore, the proposed algo-
rithm propagating to react with antibiotic treatment on
increased uptake (instead of adjusting immunosuppressives)
cannot be unequivocally supported.Wewould encourage the
authors to compile all the important immunological data and
to continue their very important research in this field.
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Response to comment regarding “Immunosuppression
Following Fresh Arterial Homograft Implantation for
Aortic Graft Infections”We would like to thank you for the interesting comment
about our article. In our study tissue histocompatibility,
ABO compatibility and cross-match were carried out in
every patient. All our patients received ABO compatible
grafts. There was no statistical difference in tissue histo-
compatibility between both groups.
We believe that the ABO compatibility for FAH is
needed, while there are no convincing data that it does not
affect the graft viability. We also assume that immuno-
suppressive treatment helps to stop the degradation of the
arterial wall and prolongs its viability of FAH.1 We observed
that the lack or discontinuation of intake of these medi-
caments caused the degradation of the arterial graft’s wall
and loss of the endothelial cells. Azuma et al. made the
same observation in his experimental trial.2
Prolonged antibiotic therapy and cyclosporine A did not
cause any complications associated with the decreased
immunity. The increase of the accumulation of the labeled
leucocytes around the homograft can be regarded as the
chronic reaction against the foreign tissue or an infective
process. We think that new experimental studies that include
immunosuppressive drugs and antibiotic dosage adjustment
and new diagnosticmethods are essential to solve the problem
of the best therapeutic options for patients with aortic graft
infections. We are going to present more detailed information
about the problem of immunosuppression following FAH
implantation for aortic graft infections in our next article.
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